995.6K XNAS Volume
XNAS 03 Apr, 2025 5:30 PM (EDT)
| Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|
| Erin Moore | Interim PFO and PAO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Mar 2025 | 5,000 | 11,764 | - | - | Stock Option (Right to Buy) | |
| Erin Moore | Interim PFO and PAO | Sale of securities on an exchange or to another person at price $ 33.12 per share. | 24 Mar 2025 | 13,564 | 82,609 (0%) | 0% | 33.1 | 449,237 | Common Stock |
| Erin Moore | Interim PFO and PAO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Mar 2025 | 8,564 | 40,724 | - | - | Stock Option (Right to Buy) | |
| Erin Moore | Interim PFO and PAO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 13.52 per share. | 24 Mar 2025 | 8,564 | 96,173 (0%) | 0% | 13.5 | 115,785 | Common Stock |
| Erin Moore | Interim PFO and PAO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 23.86 per share. | 24 Mar 2025 | 5,000 | 87,609 (0%) | 0% | 23.9 | 119,300 | Common Stock |
| Tracey Sacco | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Mar 2025 | 5,000 | 190,000 | - | - | Stock Option (Right to Buy) | |
| Tracey Sacco | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 32.89 per share. | 24 Mar 2025 | 5,000 | 71,750 (0%) | 0% | 32.9 | 164,459 | Common Stock |
| Tracey Sacco | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 33.70 per share. | 24 Mar 2025 | 1,500 | 76,750 (0%) | 0% | 33.7 | 50,556 | Common Stock |
| Tracey Sacco | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.00 per share. | 24 Mar 2025 | 5,000 | 78,250 (0%) | 0% | 10 | 50,000 | Common Stock |
| Katie Peng | Director | Sale of securities on an exchange or to another person at price $ 34.42 per share. | 17 Mar 2025 | 1,006 | 30,319 (0%) | 0% | 34.4 | 34,627 | Common Stock |
| Edward H. Myles | COO & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 13.83 per share. | 10 Mar 2025 | 21,690 | 162,430 (0%) | 0% | 13.8 | 299,973 | Common Stock |
| Edward H. Myles | COO & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2025 | 17,857 | 53,573 | - | - | Stock Option (Right to Buy) | |
| Edward H. Myles | COO & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2025 | 5,313 | 42,500 | - | - | Stock Option (Right to Buy) | |
| Edward H. Myles | COO & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2025 | 24,915 | 12,462 | - | - | Stock Option (Right to Buy) | |
| Edward H. Myles | COO & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2025 | 43,122 | 14,378 | - | - | Stock Option (Right to Buy) | |
| Edward H. Myles | COO & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2025 | 21,690 | 0 | - | - | Stock Option (Right to Buy) | |
| Edward H. Myles | COO & CFO | Sale of securities on an exchange or to another person at price $ 34.87 per share. | 10 Mar 2025 | 29,395 | 111,345 (0%) | 0% | 34.9 | 1,025,004 | Common Stock |
| Edward H. Myles | COO & CFO | Sale of securities on an exchange or to another person at price $ 35.82 per share. | 10 Mar 2025 | 112,897 | 140,740 (0%) | 0% | 35.8 | 4,043,971 | Common Stock |
| Edward H. Myles | COO & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 15.75 per share. | 10 Mar 2025 | 17,857 | 253,637 (0%) | 0% | 15.8 | 281,248 | Common Stock |
| Edward H. Myles | COO & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.00 per share. | 10 Mar 2025 | 5,313 | 235,780 (0%) | 0% | 10 | 53,130 | Common Stock |
| Edward H. Myles | COO & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.86 per share. | 10 Mar 2025 | 24,915 | 230,467 (0%) | 0% | 4.9 | 121,087 | Common Stock |
| Edward H. Myles | COO & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 18.08 per share. | 10 Mar 2025 | 43,122 | 205,552 (0%) | 0% | 18.1 | 779,646 | Common Stock |
| Jay T. Backstrom | Director, CHIEF EXECUTIVE OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2025 | 151,430 | 151,430 | - | - | Stock Option (Right to Buy) | |
| Jay T. Backstrom | Director, CHIEF EXECUTIVE OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2025 | 113,570 | 425,561 (1%) | 0% | 0 | Common Stock | |
| Mohammed Qatanani | CHIEF SCIENTIFIC OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2025 | 42,855 | 42,855 | - | - | Stock Option (Right to Buy) | |
| Mohammed Qatanani | CHIEF SCIENTIFIC OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2025 | 32,145 | 143,229 (0%) | 0% | 0 | Common Stock | |
| Jing L. Marantz | CHIEF MEDICAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2025 | 34,285 | 101,485 (0%) | 0% | 0 | Common Stock | |
| Jing L. Marantz | CHIEF MEDICAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2025 | 45,715 | 45,715 | - | - | Stock Option (Right to Buy) | |
| Junlin Ho | GENERAL COUNSEL | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2025 | 32,145 | 221,440 (0%) | 0% | 0 | Common Stock | |
| Junlin Ho | GENERAL COUNSEL | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2025 | 42,855 | 42,855 | - | - | Stock Option (Right to Buy) | |
| Caryn Parlavecchio | CHRO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2025 | 23,570 | 163,828 (0%) | 0% | 0 | Common Stock | |
| Caryn Parlavecchio | CHRO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2025 | 31,430 | 31,430 | - | - | Stock Option (Right to Buy) | |
| Tracey Sacco | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2025 | 37,145 | 37,145 | - | - | Stock Option (Right to Buy) | |
| Tracey Sacco | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2025 | 27,855 | 73,250 (0%) | 0% | 0 | Common Stock | |
| Edward H. Myles | COO & CFO | Sale of securities on an exchange or to another person at price $ 36.83 per share. | 18 Feb 2025 | 7,809 | 140,740 (0%) | 0% | 36.8 | 287,598 | Common Stock |
| Jay T. Backstrom | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 36.83 per share. | 18 Feb 2025 | 18,372 | 311,991 (1%) | 0% | 36.8 | 676,622 | Common Stock |
| Mohammed Qatanani | CHIEF SCIENTIFIC OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2025 | 17,678 | 76,607 | - | - | Stock Option (Right to Buy) | |
| Mohammed Qatanani | CHIEF SCIENTIFIC OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.62 per share. | 18 Feb 2025 | 2,562 | 150,666 (0%) | 0% | 7.6 | 19,522 | Common Stock |
| Mohammed Qatanani | CHIEF SCIENTIFIC OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.00 per share. | 18 Feb 2025 | 11,250 | 161,916 (0%) | 0% | 10 | 112,500 | Common Stock |
| Mohammed Qatanani | CHIEF SCIENTIFIC OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 15.75 per share. | 18 Feb 2025 | 17,678 | 179,594 (0%) | 0% | 15.8 | 278,429 | Common Stock |
| Mohammed Qatanani | CHIEF SCIENTIFIC OFFICER | Sale of securities on an exchange or to another person at price $ 37.20 per share. | 18 Feb 2025 | 39,967 | 139,627 (0%) | 0% | 37.2 | 1,486,692 | Common Stock |
| Mohammed Qatanani | CHIEF SCIENTIFIC OFFICER | Sale of securities on an exchange or to another person at price $ 37.56 per share. | 18 Feb 2025 | 8,341 | 131,286 (0%) | 0% | 37.6 | 313,289 | Common Stock |
| Mohammed Qatanani | CHIEF SCIENTIFIC OFFICER | Sale of securities on an exchange or to another person at price $ 37.74 per share. | 18 Feb 2025 | 20,202 | 111,084 (0%) | 0% | 37.7 | 762,498 | Common Stock |
| Mohammed Qatanani | CHIEF SCIENTIFIC OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2025 | 16,818 | 5,607 | - | - | Stock Option (Right to Buy) | |
| Mohammed Qatanani | CHIEF SCIENTIFIC OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2025 | 2,562 | 2,563 | - | - | Stock Option (Right to Buy) | |
| Mohammed Qatanani | CHIEF SCIENTIFIC OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2025 | 11,250 | 25,313 | - | - | Stock Option (Right to Buy) | |
| Mohammed Qatanani | CHIEF SCIENTIFIC OFFICER | Sale of securities on an exchange or to another person at price $ 36.83 per share. | 18 Feb 2025 | 4,135 | 131,286 (0%) | 0% | 36.8 | 152,288 | Common Stock |
| Mohammed Qatanani | CHIEF SCIENTIFIC OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.86 per share. | 18 Feb 2025 | 16,818 | 148,104 (0%) | 0% | 4.9 | 81,735 | Common Stock |
| Junlin Ho | GENERAL COUNSEL | Sale of securities on an exchange or to another person at price $ 36.83 per share. | 18 Feb 2025 | 5,742 | 189,295 (0%) | 0% | 36.8 | 211,472 | Common Stock |
| Caryn Parlavecchio | CHRO | Sale of securities on an exchange or to another person at price $ 36.83 per share. | 18 Feb 2025 | 5,296 | 140,258 (0%) | 0% | 36.8 | 195,046 | Common Stock |
| Edward H. Myles | COO & CFO | Sale of securities on an exchange or to another person at price $ 44.20 per share. | 16 Jan 2025 | 12,539 | 148,549 (0%) | 0% | 44.2 | 554,189 | Common Stock |
| Jay T. Backstrom | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 44.20 per share. | 16 Jan 2025 | 22,308 | 330,363 (1%) | 0% | 44.2 | 985,951 | Common Stock |
| Mohammed Qatanani | CHIEF SCIENTIFIC OFFICER | Sale of securities on an exchange or to another person at price $ 44.20 per share. | 16 Jan 2025 | 7,347 | 135,421 (0%) | 0% | 44.2 | 324,717 | Common Stock |
| Jing L. Marantz | CHIEF MEDICAL OFFICER | Sale of securities on an exchange or to another person at price $ 44.20 per share. | 16 Jan 2025 | 5,655 | 67,200 (0%) | 0% | 44.2 | 249,935 | Common Stock |
| Junlin Ho | GENERAL COUNSEL | Sale of securities on an exchange or to another person at price $ 44.20 per share. | 16 Jan 2025 | 9,039 | 195,037 (0%) | 0% | 44.2 | 399,498 | Common Stock |
| Caryn Parlavecchio | CHRO | Sale of securities on an exchange or to another person at price $ 44.20 per share. | 16 Jan 2025 | 6,434 | 145,554 (0%) | 0% | 44.2 | 284,365 | Common Stock |
| Tracey Sacco | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 44.20 per share. | 16 Jan 2025 | 3,890 | 45,395 (0%) | 0% | 44.2 | 171,927 | Common Stock |
| Jing L. Marantz | CHIEF MEDICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.59 per share. | 22 Nov 2024 | 2,145 | 75,000 (0%) | 0% | 8.6 | 18,426 | Common Stock |
| Jing L. Marantz | CHIEF MEDICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Nov 2024 | 2,145 | 136,375 | - | - | Stock Option (Right to Buy) | |
| Jing L. Marantz | CHIEF MEDICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Nov 2024 | 6,375 | 130,000 | - | - | Stock Option (Right to Buy) | |
| Jing L. Marantz | CHIEF MEDICAL OFFICER | Sale of securities on an exchange or to another person at price $ 40.72 per share. | 22 Nov 2024 | 200 | 72,855 (0%) | 0% | 40.7 | 8,144 | Common Stock |
| Jing L. Marantz | CHIEF MEDICAL OFFICER | Sale of securities on an exchange or to another person at price $ 39.93 per share. | 22 Nov 2024 | 3,075 | 73,055 (0%) | 0% | 39.9 | 122,780 | Common Stock |
| Jing L. Marantz | CHIEF MEDICAL OFFICER | Sale of securities on an exchange or to another person at price $ 39.25 per share. | 22 Nov 2024 | 2,100 | 76,130 (0%) | 0% | 39.3 | 82,434 | Common Stock |
| Jing L. Marantz | CHIEF MEDICAL OFFICER | Sale of securities on an exchange or to another person at price $ 38.04 per share. | 22 Nov 2024 | 1,000 | 78,230 (0%) | 0% | 38.0 | 38,041 | Common Stock |
| Jing L. Marantz | CHIEF MEDICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.59 per share. | 22 Nov 2024 | 6,375 | 79,230 (0%) | 0% | 8.6 | 54,761 | Common Stock |
| Jing L. Marantz | CHIEF MEDICAL OFFICER | Sale of securities on an exchange or to another person at price $ 30.01 per share. | 22 Nov 2024 | 2,145 | 72,855 (0%) | 0% | 30.0 | 64,372 | Common Stock |
| Michael Gilman | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 12 Nov 2024 | 37,459 | 50,959 (0%) | 0% | - | Common Stock | |
| Michael Gilman | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 12 Nov 2024 | 37,459 | 0 (0%) | 0% | - | Common Stock | |
| Jing L. Marantz | CHIEF MEDICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.59 per share. | 11 Nov 2024 | 2,105 | 74,960 (0%) | 0% | 8.6 | 18,082 | Common Stock |
| Jing L. Marantz | CHIEF MEDICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Nov 2024 | 2,105 | 138,520 | - | - | Stock Option (Right to Buy) | |
| Jing L. Marantz | CHIEF MEDICAL OFFICER | Sale of securities on an exchange or to another person at price $ 30.00 per share. | 11 Nov 2024 | 2,105 | 72,855 (0%) | 0% | 30.0 | 63,158 | Common Stock |
| Edward H. Myles | COO & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Oct 2024 | 37,187 | 47,813 | - | - | Stock Option (Right to Buy) | |
| Edward H. Myles | COO & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.00 per share. | 08 Oct 2024 | 37,187 | 198,275 (0%) | 0% | 10 | 371,870 | Common Stock |
| Edward H. Myles | COO & CFO | Sale of securities on an exchange or to another person at price $ 34.90 per share. | 08 Oct 2024 | 37,187 | 161,088 (0%) | 0% | 34.9 | 1,297,659 | Common Stock |
| Edward H. Myles | COO & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 13.83 per share. | 07 Oct 2024 | 206,240 | 367,328 (1%) | 0% | 13.8 | 2,852,299 | Common Stock |
| Edward H. Myles | COO & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Oct 2024 | 165,810 | 0 | - | - | Stock Option (Right to Buy) | |
| Edward H. Myles | COO & CFO | Sale of securities on an exchange or to another person at price $ 29.05 per share. | 07 Oct 2024 | 31,250 | 161,088 (0%) | 0% | 29.1 | 907,813 | Common Stock |
| Edward H. Myles | COO & CFO | Sale of securities on an exchange or to another person at price $ 27.27 per share. | 07 Oct 2024 | 25,812 | 192,338 (0%) | 0% | 27.3 | 703,893 | Common Stock |
| Edward H. Myles | COO & CFO | Sale of securities on an exchange or to another person at price $ 26.83 per share. | 07 Oct 2024 | 37,206 | 218,150 (0%) | 0% | 26.8 | 998,237 | Common Stock |
| Edward H. Myles | COO & CFO | Sale of securities on an exchange or to another person at price $ 25.61 per share. | 07 Oct 2024 | 111,972 | 255,356 (0%) | 0% | 25.6 | 2,867,603 | Common Stock |
| Srinivas Akkaraju | Director | Sale of securities on an exchange or to another person at price $ 32.50 per share. | 07 Oct 2024 | 155,713 | 5,612,896 (18%) | 0% | 32.5 | 5,060,673 | Common Stock |
| Srinivas Akkaraju | Director | Sale of securities on an exchange or to another person at price $ 27.50 per share. | 07 Oct 2024 | 510,000 | 6,278,609 (21%) | 1% | 27.5 | 14,025,000 | Common Stock |
| Srinivas Akkaraju | Director | Sale of securities on an exchange or to another person at price $ 30.00 per share. | 07 Oct 2024 | 510,000 | 5,768,609 (19%) | 1% | 30 | 15,300,000 | Common Stock |
| Jing L. Marantz | CHIEF MEDICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.59 per share. | 07 Oct 2024 | 109,375 | 182,230 (0%) | 0% | 8.6 | 939,531 | Common Stock |
| Jing L. Marantz | CHIEF MEDICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Oct 2024 | 109,375 | 140,625 | - | - | Stock Option (Right to Buy) | |
| Jing L. Marantz | CHIEF MEDICAL OFFICER | Sale of securities on an exchange or to another person at price $ 30.06 per share. | 07 Oct 2024 | 39,375 | 72,855 (0%) | 0% | 30.1 | 1,183,652 | Common Stock |
| Jing L. Marantz | CHIEF MEDICAL OFFICER | Sale of securities on an exchange or to another person at price $ 26.22 per share. | 07 Oct 2024 | 2,552 | 112,230 (0%) | 0% | 26.2 | 66,923 | Common Stock |
| Jing L. Marantz | CHIEF MEDICAL OFFICER | Sale of securities on an exchange or to another person at price $ 25.59 per share. | 07 Oct 2024 | 67,448 | 114,782 (0%) | 0% | 25.6 | 1,725,893 | Common Stock |
| Tracey Sacco | CHIEF COMMERCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.00 per share. | 07 Oct 2024 | 30,000 | 79,285 (0%) | 0% | 10 | 300,000 | Common Stock |
| Tracey Sacco | CHIEF COMMERCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 25.58 per share. | 07 Oct 2024 | 28,036 | 51,249 (0%) | 0% | 25.6 | 717,161 | Common Stock |
| Tracey Sacco | CHIEF COMMERCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 26.23 per share. | 07 Oct 2024 | 1,964 | 49,285 (0%) | 0% | 26.2 | 51,516 | Common Stock |
| Tracey Sacco | CHIEF COMMERCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Oct 2024 | 30,000 | 140,625 | - | - | Stock Option (Right to Buy) | |
| Mohammed Qatanani | CHIEF SCIENTIFIC OFFICER | Sale of securities on an exchange or to another person at price $ 8.58 per share. | 16 Sep 2024 | 1,936 | 142,768 (0%) | 0% | 8.6 | 16,611 | Common Stock |
| Caryn Parlavecchio | CHRO | Sale of securities on an exchange or to another person at price $ 9.33 per share. | 16 Aug 2024 | 1,451 | 151,988 (0%) | 0% | 9.3 | 13,538 | Common Stock |
| Michael Gilman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2024 | 18,000 | 18,000 | - | - | Stock Option (Right to Buy) | |
| Michael Gilman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2024 | 13,500 | 13,500 (0%) | 0% | 0 | Common Stock | |
| David L. Hallal | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2024 | 18,000 | 18,000 | - | - | Stock Option (Right to Buy) | |
| David L. Hallal | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2024 | 13,500 | 304,095 (1%) | 0% | 0 | Common Stock | |
| Srinivas Akkaraju | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2024 | 18,000 | 18,000 | - | - | Stock Option (Right to Buy) | |
| Srinivas Akkaraju | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2024 | 13,500 | 13,500 (0%) | 0% | 0 | Common Stock | |
| Akshay K. Vaishnaw | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2024 | 13,500 | 22,955 (0%) | 0% | 0 | Common Stock | |
| Akshay K. Vaishnaw | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2024 | 18,000 | 18,000 | - | - | Stock Option (Right to Buy) | |
| Kristina M. Burow | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2024 | 18,000 | 18,000 | - | - | Stock Option (Right to Buy) | |
| Kristina M. Burow | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2024 | 13,500 | 18,839 (0%) | 0% | 0 | Common Stock | |
| Richard H. Brudnick | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2024 | 13,500 | 13,500 (0%) | 0% | 0 | Common Stock | |
| Richard H. Brudnick | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2024 | 18,000 | 18,000 | - | - | Stock Option (Right to Buy) | |
| Jeffrey S. Flier | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2024 | 18,000 | 18,000 | - | - | Stock Option (Right to Buy) | |
| Jeffrey S. Flier | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2024 | 13,500 | 22,513 (0%) | 0% | 0 | Common Stock | |
| Joshua Reed | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2024 | 13,500 | 13,500 (0%) | 0% | 0 | Common Stock | |
| Joshua Reed | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2024 | 18,000 | 18,000 | - | - | Stock Option (Right to Buy) | |
| Katie Peng | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2024 | 4,500 | 31,325 (0%) | 0% | 0 | Common Stock | |
| Katie Peng | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2024 | 6,000 | 6,000 | - | - | Stock Option (Right to Buy) | |
| Edward H. Myles | COO & CFO | Sale of securities on an exchange or to another person at price $ 8.98 per share. | 17 Jun 2024 | 9,458 | 201,518 (0%) | 0% | 9.0 | 84,978 | Common Stock |
| Mohammed Qatanani | CHIEF SCIENTIFIC OFFICER | Sale of securities on an exchange or to another person at price $ 8.98 per share. | 17 Jun 2024 | 2,315 | 144,704 (0%) | 0% | 9.0 | 20,800 | Common Stock |
| Junlin Ho | GENERAL COUNSEL | Sale of securities on an exchange or to another person at price $ 8.98 per share. | 17 Jun 2024 | 4,695 | 204,076 (0%) | 0% | 9.0 | 42,183 | Common Stock |
| Caryn Parlavecchio | CHRO | Sale of securities on an exchange or to another person at price $ 8.98 per share. | 17 Jun 2024 | 4,305 | 153,439 (0%) | 0% | 9.0 | 38,680 | Common Stock |
| Amir H. Nashat | Director | Other type of transaction at price $ 0.00 per share. | 09 May 2024 | 322 | 1,469 (0%) | 0% | 0 | Common Stock | |
| Amir H. Nashat | Director | Other type of transaction at price $ 0.00 per share. | 09 May 2024 | 472,394 | 1,650,953 (5%) | 1% | 0 | Common Stock | |
| Amir H. Nashat | Director | Other type of transaction at price $ 0.00 per share. | 09 May 2024 | 276 | 0 (0%) | 0% | 0 | Common Stock | |
| Amir H. Nashat | Director | Other type of transaction at price $ 0.00 per share. | 09 May 2024 | 276 | 276 (0%) | 0% | 0 | Common Stock | |
| Amir H. Nashat | Director | Other type of transaction at price $ 0.00 per share. | 09 May 2024 | 98,257 | 98,257 (0%) | 0% | 0 | Common Stock | |
| Amir H. Nashat | Director | Other type of transaction at price $ 0.00 per share. | 09 May 2024 | 37 | 38,639 (0%) | 0% | 0 | Common Stock | |
| Amir H. Nashat | Director | Other type of transaction at price $ 0.00 per share. | 09 May 2024 | 98,257 | 0 (0%) | 0% | 0 | Common Stock | |
| Amir H. Nashat | Director | Other type of transaction at price $ 0.00 per share. | 09 May 2024 | 13,096 | 38,602 (0%) | 0% | 0 | Common Stock | |
| Amir H. Nashat | Director | Other type of transaction at price $ 0.00 per share. | 09 May 2024 | 27,606 | 96,474 (0%) | 0% | 0 | Common Stock | |
| Katie Peng | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Apr 2024 | 35,767 | 35,767 | - | - | Stock Option (Right to Buy) | |
| Katie Peng | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Apr 2024 | 26,825 | 26,825 (0%) | 0% | 0 | Common Stock | |
| Edward H. Myles | COO & CFO | Sale of securities on an exchange or to another person at price $ 15.74 per share. | 16 Feb 2024 | 4,744 | 210,976 (0%) | 0% | 15.7 | 74,686 | Common Stock |
| Jay T. Backstrom | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 15.74 per share. | 16 Feb 2024 | 11,614 | 352,671 (1%) | 0% | 15.7 | 182,842 | Common Stock |
| Mohammed Qatanani | CHIEF SCIENTIFIC OFFICER | Sale of securities on an exchange or to another person at price $ 15.74 per share. | 16 Feb 2024 | 2,512 | 147,019 (0%) | 0% | 15.7 | 39,547 | Common Stock |
| Caryn Parlavecchio | CHRO | Sale of securities on an exchange or to another person at price $ 15.74 per share. | 16 Feb 2024 | 3,751 | 157,744 (0%) | 0% | 15.7 | 59,053 | Common Stock |
| Junlin Ho | GENERAL COUNSEL | Sale of securities on an exchange or to another person at price $ 15.74 per share. | 16 Feb 2024 | 3,489 | 208,771 (0%) | 0% | 15.7 | 54,928 | Common Stock |
| Junlin Ho | GENERAL COUNSEL | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2024 | 57,855 | 212,260 (0%) | 0% | 0 | Common Stock | |
| Ho Junlin | GENERAL COUNSEL | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2024 | 77,145 | 77,145 | - | - | Stock Option (Right to Buy) | |
| Mohammed Qatanani | CHIEF SCIENTIFIC OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2024 | 94,285 | 94,285 | - | - | Stock Option (Right to Buy) | |
| Sacco Tracey | CHIEF COMMERCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2024 | 65,715 | 65,715 | - | - | Stock Option (Right to Buy) | |
| H. Edward Myles | COO & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2024 | 71,430 | 71,430 | - | - | Stock Option (Right to Buy) | |
| Caryn Parlavecchio | CHRO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2024 | 62,855 | 62,855 | - | - | Stock Option (Right to Buy) | |
| Jing L. Marantz | CHIEF MEDICAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2024 | 97,145 | 97,145 | - | - | Stock Option (Right to Buy) | |
| Caryn Parlavecchio | CHRO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2024 | 47,145 | 161,495 (0%) | 0% | 0 | Common Stock | |
| L. Jing Marantz | CHIEF MEDICAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2024 | 72,855 | 72,855 (0%) | 0% | 0 | Common Stock | |
| Jay Backstrom T. | Director, CHIEF EXECUTIVE OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2024 | 214,285 | 364,285 (1%) | 0% | 0 | Common Stock | |
| Qatanani Mohammed | CHIEF SCIENTIFIC OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2024 | 70,715 | 149,531 (0%) | 0% | 0 | Common Stock | |
| Tracey Sacco | CHIEF COMMERCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2024 | 49,285 | 49,285 (0%) | 0% | 0 | Common Stock | |
| Jay T. Backstrom | Director, CHIEF EXECUTIVE OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2024 | 285,715 | 285,715 | - | - | Stock Option (Right to Buy) | |
| Myles H. Edward | COO & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2024 | 53,570 | 215,720 (0%) | 0% | 0 | Common Stock | |
| Myles H. Edward | COO & CFO | Sale of securities on an exchange or to another person at price $ 15.93 per share. | 16 Jan 2024 | 6,634 | 162,150 (0%) | 0% | 15.9 | 105,670 | Common Stock |
| Mohammed Qatanani | SVP AND HEAD OF RESEARCH | Sale of securities on an exchange or to another person at price $ 15.93 per share. | 16 Jan 2024 | 2,002 | 78,816 (0%) | 0% | 15.9 | 31,889 | Common Stock |
| Junlin Ho | GENERAL COUNSEL | Sale of securities on an exchange or to another person at price $ 15.93 per share. | 16 Jan 2024 | 4,186 | 154,405 (0%) | 0% | 15.9 | 66,677 | Common Stock |
| Caryn Parlavecchio | CHRO | Sale of securities on an exchange or to another person at price $ 15.93 per share. | 16 Jan 2024 | 2,849 | 114,350 (0%) | 0% | 15.9 | 45,381 | Common Stock |
| H. Myles Edward | COO & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Dec 2023 | 24,914 | 49,836 | - | - | Stock Option (Right to Buy) | |
| H. Edward Myles | COO & CFO | Sale of securities on an exchange or to another person at price $ 19.51 per share. | 29 Dec 2023 | 300 | 168,784 (0%) | 0% | 19.5 | 5,853 | Common Stock |
| Edward H. Myles | COO & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.86 per share. | 29 Dec 2023 | 12,459 | 181,243 (0%) | 0% | 4.9 | 60,551 | Common Stock |
| Myles H. Edward | COO & CFO | Sale of securities on an exchange or to another person at price $ 18.82 per share. | 29 Dec 2023 | 12,159 | 169,084 (0%) | 0% | 18.8 | 228,780 | Common Stock |
| H. Nashat Amir | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 27 Dec 2023 | 21,333 | 25,506 (0%) | 0% | 0 | Common Stock | |
| Burow M. Kristina | Director | Other type of transaction at price $ 0.00 per share. | 21 Dec 2023 | 5,339 | 5,339 (0%) | 0% | 0 | Common Stock | |
| M. Kristina Burow | Director | Other type of transaction at price $ 0.00 per share. | 21 Dec 2023 | 291,906 | 2,345,711 (7%) | 0% | 0 | Common Stock | |
| Mohammed Qatanani | SVP AND HEAD OF RESEARCH | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Dec 2023 | 8,437 | 36,563 | - | - | Stock Option (Right to Buy) | |
| Qatanani Mohammed | SVP AND HEAD OF RESEARCH | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.00 per share. | 14 Dec 2023 | 8,437 | 105,480 (0%) | 0% | 10 | 84,370 | Common Stock |
| Qatanani Mohammed | SVP AND HEAD OF RESEARCH | Sale of securities on an exchange or to another person at price $ 18.18 per share. | 14 Dec 2023 | 24,662 | 80,818 (0%) | 0% | 18.2 | 448,444 | Common Stock |
| Nashat Amir H. | Director | Other type of transaction at price $ 0.00 per share. | 13 Dec 2023 | 196,520 | 0 (0%) | 0% | 0 | Common Stock | |
| Amir Nashat H. | Director | Other type of transaction at price $ 0.00 per share. | 13 Dec 2023 | 548 | 548 (0%) | 0% | 0 | Common Stock | |
| Nashat Amir H. | Director | Other type of transaction at price $ 0.00 per share. | 13 Dec 2023 | 643 | 1,147 (0%) | 0% | 0 | Common Stock | |
| H. Nashat Amir | Director | Other type of transaction at price $ 0.00 per share. | 13 Dec 2023 | 55,211 | 124,080 (0%) | 0% | 0 | Common Stock | |
| Amir Nashat H. | Director | Other type of transaction at price $ 0.00 per share. | 13 Dec 2023 | 196,520 | 196,520 (0%) | 0% | 0 | Common Stock | |
| Amir H. Nashat | Director | Other type of transaction at price $ 0.00 per share. | 13 Dec 2023 | 548 | 0 (0%) | 0% | 0 | Common Stock | |
| H. Nashat Amir | Director | Other type of transaction at price $ 0.00 per share. | 13 Dec 2023 | 73 | 46,839 (0%) | 0% | 0 | Common Stock | |
| H. Nashat Amir | Director | Other type of transaction at price $ 0.00 per share. | 13 Dec 2023 | 26,192 | 46,766 (0%) | 0% | 0 | Common Stock | |
| H. Nashat Amir | Director | Other type of transaction at price $ 0.00 per share. | 13 Dec 2023 | 944,789 | 2,123,347 (7%) | 3% | 0 | Common Stock | |
| Myles Edward H. | COO & CFO | Sale of securities on an exchange or to another person at price $ 17.53 per share. | 07 Dec 2023 | 24,914 | 168,784 (0%) | 0% | 17.5 | 436,820 | Common Stock |
| Myles Edward H. | COO & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.86 per share. | 07 Dec 2023 | 24,914 | 193,698 (0%) | 0% | 4.9 | 121,082 | Common Stock |
| Myles H. Edward | COO & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Dec 2023 | 24,914 | 49,836 | - | - | Stock Option (Right to Buy) | |
| Caryn Parlavecchio | CHRO | Sale of securities on an exchange or to another person at price $ 6.83 per share. | 16 Aug 2023 | 1,353 | 117,199 (0%) | 0% | 6.8 | 9,241 | Common Stock |
| Edward H. Myles | COO & CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.75 per share. | 21 Jun 2023 | 7,138 | 203,791 (0%) | 0% | 8.7 | 62,456 | Common Stock |
| Michael Gilman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2023 | 36,000 | 36,000 | - | - | Stock Option (Right to Buy) | |
| David Hallal | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2023 | 36,000 | 36,000 | - | - | Stock Option (Right to Buy) | |
| Srinivas Akkaraju | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2023 | 36,000 | 36,000 | - | - | Stock Option (Right to Buy) | |
| Akshay K. Vaishnaw | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2023 | 36,000 | 36,000 | - | - | Stock Option (Right to Buy) | |
| Kristina M. Burow | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2023 | 36,000 | 36,000 | - | - | Stock Option (Right to Buy) | |
| Amir H. Nashat | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2023 | 36,000 | 36,000 | - | - | Stock Option (Right to Buy) | |
| Jeffrey S. Flier | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2023 | 36,000 | 36,000 | - | - | Stock Option (Right to Buy) | |
| Joshua Reed | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2023 | 36,000 | 36,000 | - | - | Stock Option (Right to Buy) | |
| Junlin Ho | GENERAL COUNSEL | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.75 per share. | 21 Jun 2023 | 4,346 | 158,591 (0%) | 0% | 8.7 | 38,027 | Common Stock |
| Caryn Parlavecchio | CHRO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.75 per share. | 21 Jun 2023 | 4,038 | 118,552 (0%) | 0% | 8.7 | 35,332 | Common Stock |
| Richard H. Brudnick | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Apr 2023 | 56,000 | 56,000 | - | - | Stock Option (Right to Buy) | |
| Edward H. Myles | COO & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2023 | 63,750 | 210,929 (0%) | 0% | 0 | Common Stock | |
| Edward H. Myles | COO & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2023 | 85,000 | 85,000 | - | - | Stock Option (Right to Buy) | |
| Jay T. Backstrom | CHIEF EXECUTIVE OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2023 | 150,000 | 150,000 (0%) | 0% | 0 | Common Stock | |
| Jay T. Backstrom | CHIEF EXECUTIVE OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2023 | 200,000 | 200,000 | - | - | Stock Option (Right to Buy) | |
| Junlin Ho | GENERAL COUNSEL | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2023 | 62,500 | 62,500 | - | - | Stock Option (Right to Buy) | |
| Junlin Ho | GENERAL COUNSEL | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2023 | 46,875 | 162,937 (0%) | 0% | 0 | Common Stock | |
| Caryn Parlavecchio | CHRO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2023 | 46,875 | 122,590 (0%) | 0% | 0 | Common Stock | |
| Caryn Parlavecchio | CHRO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2023 | 62,500 | 62,500 | - | - | Stock Option (Right to Buy) | |
| Edward H. Myles | COO & CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.29 per share. | 17 Jan 2023 | 7,043 | 147,179 (0%) | 0% | 11.3 | 79,503 | Common Stock |
| Junlin Ho | GENERAL COUNSEL | Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.29 per share. | 17 Jan 2023 | 4,529 | 116,062 (0%) | 0% | 11.3 | 51,125 | Common Stock |
| Caryn Parlavecchio | CHRO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.28 per share. | 17 Jan 2023 | 2,934 | 75,715 (0%) | 0% | 11.3 | 33,096 | Common Stock |
| Jing L. Marantz | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Nov 2022 | 250,000 | 250,000 | - | - | Stock Option (right to buy) | |
| Jay T. Backstrom | CEO-Elect | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Sep 2022 | 1,000,000 | 1,000,000 | - | - | Stock Option (right to buy) | |
| Srinivas Akkaraju | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Sep 2022 | 56,000 | 56,000 | - | - | Stock Option (Right to Buy) | |
| Caryn Parlavecchio | CHRO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.34 per share. | 16 Aug 2022 | 1,401 | 78,649 (0%) | 0% | 11.3 | 15,887 | Common Stock |
| Michael Gilman | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 08 Jul 2022 | 37,459 | 37,459 (0%) | 0% | - | Common Stock | |
| Michael Gilman | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 08 Jul 2022 | 37,459 | 0 (0%) | 0% | - | Common Stock | |
| Amir H. Nashat | Director | Purchase of securities on an exchange or from another person at price $ 4.90 per share. | 22 Jun 2022 | 66,142 | 206,897 (0%) | 0% | 4.9 | 324,096 | Common Stock |
| Amir H. Nashat | Director | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 22 Jun 2022 | 16,536 | 16,536 | - | - | Common Warrant (right to buy) | |
| Amir H. Nashat | Director | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 22 Jun 2022 | 282,962 | 282,962 | - | - | Common Warrant (right to buy) | |
| Amir H. Nashat | Director | Purchase of securities on an exchange or from another person at price $ 4.90 per share. | 22 Jun 2022 | 1,131,850 | 3,540,530 (11%) | 3% | 4.9 | 5,546,065 | Common Stock |
| Edward H. Myles | COO & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2022 | 74,750 | 74,750 | - | - | Stock Option (Right to Buy) | |
| Edward H. Myles | COO & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2022 | 74,750 | 154,222 (0%) | 0% | 0 | Common Stock | |
| Michael Gilman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2022 | 14,000 | 14,000 | - | - | Stock Option (Right to Buy) | |
| David Hallal | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2022 | 14,000 | 14,000 | - | - | Stock Option (Right to Buy) | |
| Akshay K. Vaishnaw | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2022 | 14,000 | 14,000 | - | - | Stock Option (Right to Buy) | |
| Nagesh K. Mahanthappa | Interim CEO and President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2022 | 50,000 | 50,000 | - | - | Stock Option (Right to Buy) | |
| Nagesh K. Mahanthappa | Interim CEO and President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2022 | 50,000 | 480,491 (1%) | 0% | 0 | Common Stock | |
| Gregory John Carven | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2022 | 45,500 | 45,500 | - | - | Stock Option (Right to Buy) | |
| Gregory John Carven | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2022 | 45,500 | 128,208 (0%) | 0% | 0 | Common Stock | |
| Junlin Ho | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2022 | 45,500 | 45,500 | - | - | Stock Option (Right to Buy) | |
| Junlin Ho | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2022 | 45,500 | 120,591 (0%) | 0% | 0 | Common Stock | |
| Caryn Parlavecchio | CHRO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2022 | 35,750 | 80,050 (0%) | 0% | 0 | Common Stock | |
| Caryn Parlavecchio | CHRO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2022 | 35,750 | 35,750 | - | - | Stock Option (Right to Buy) | |
| Michael Gilman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 May 2022 | 28,000 | 28,000 | - | - | Stock Option (Right to Buy) | |
| David Hallal | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 May 2022 | 28,000 | 28,000 | - | - | Stock Option (Right to Buy) | |
| Akshay K. Vaishnaw | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 May 2022 | 28,000 | 28,000 | - | - | Stock Option (Right to Buy) | |
| Kristina M. Burow | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 May 2022 | 28,000 | 28,000 | - | - | Stock Option (Right to Buy) | |
| Amir H. Nashat | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 May 2022 | 28,000 | 28,000 | - | - | Stock Option (Right to Buy) | |
| Jeffrey S. Flier | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 May 2022 | 28,000 | 28,000 | - | - | Stock Option (Right to Buy) | |
| Joshua Reed | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 May 2022 | 28,000 | 28,000 | - | - | Stock Option (Right to Buy) | |
| Edward H. Myles | COO & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2022 | 57,500 | 79,472 (0%) | 0% | 0 | Common Stock | |
| Edward H. Myles | COO & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2022 | 57,500 | 57,500 | - | - | Stock Option (Right to Buy) | |
| Yung H. Chyung | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2022 | 37,500 | 37,500 | - | - | Stock Option (Right to Buy) | |
| Yung H. Chyung | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2022 | 37,500 | 258,496 (0%) | 0% | 0 | Common Stock | |
| Nagesh K. Mahanthappa | Interim CEO and President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2022 | 50,000 | 50,000 (0%) | 0% | 0 | Common Stock | |
| Nagesh K. Mahanthappa | Interim CEO and President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2022 | 50,000 | 50,000 | - | - | Stock Option (Right to Buy) | |
| Gregory John Carven | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2022 | 35,000 | 35,000 | - | - | Stock Option (Right to Buy) | |
| Gregory John Carven | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2022 | 35,000 | 82,708 (0%) | 0% | 0 | Common Stock | |
| Junlin Ho | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2022 | 37,500 | 37,500 | - | - | Stock Option (Right to Buy) | |
| Junlin Ho | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2022 | 37,500 | 75,091 (0%) | 0% | 0 | Common Stock | |
| Edward H. Myles | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 19.46 per share. | 15 Jan 2022 | 2,178 | 21,972 (0%) | 0% | 19.5 | 42,390 | Common Stock |
| Yung H. Chyung | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 19.46 per share. | 15 Jan 2022 | 1,421 | 220,996 (0%) | 0% | 19.5 | 27,657 | Common Stock |
| Gregory John Carven | Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 19.46 per share. | 15 Jan 2022 | 1,137 | 47,708 (0%) | 0% | 19.5 | 22,129 | Common Stock |
| Junlin Ho | General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 19.46 per share. | 15 Jan 2022 | 1,042 | 37,591 (0%) | 0% | 19.5 | 20,280 | Common Stock |
| Edward H. Myles | Chief Financial Officer | 11 Nov 2021 | 23,574 | 47,724 (0%) | 0% | - | Common Stock | ||
| Edward H. Myles | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Nov 2021 | 4,879 | 187,500 | - | - | Stock Option (Right to Buy) | |
| Edward H. Myles | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Nov 2021 | 2,351 | 192,379 | - | - | Stock Option (Right to Buy | |
| Edward H. Myles | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Nov 2021 | 47,497 | 194,730 | - | - | Stock Option (Right to Buy) | |
| Edward H. Myles | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Nov 2021 | 7,773 | 242,227 | - | - | Stock Option (Right to Buy) | |
| Edward H. Myles | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Nov 2021 | 5,079 | 0 | - | - | Stock Option (Right to Buy) | |
| Edward H. Myles | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Nov 2021 | 10,722 | 0 | - | - | Stock Option (Right to Buy) | |
| Edward H. Myles | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 35.05 per share. | 11 Nov 2021 | 4,879 | 24,150 (0%) | 0% | 35.0 | 171,006 | Common Stock |
| Edward H. Myles | Chief Financial Officer | 11 Nov 2021 | 4,879 | 29,029 (0%) | 0% | - | Common Stock | ||
| Edward H. Myles | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 35.12 per share. | 11 Nov 2021 | 49,848 | 24,150 (0%) | 0% | 35.1 | 1,750,437 | Common Stock |
| Edward H. Myles | Chief Financial Officer | 11 Nov 2021 | 49,848 | 73,998 (0%) | 0% | - | Common Stock | ||
| Edward H. Myles | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 35.20 per share. | 11 Nov 2021 | 23,574 | 24,150 (0%) | 0% | 35.2 | 829,857 | Common Stock |
| Jeffrey S. Flier | Director | Sale of securities on an exchange or to another person at price $ 30.89 per share. | 01 Oct 2021 | 6,000 | 22,272 (0%) | 0% | 30.9 | 185,329 | Common Stock |
| Jeffrey S. Flier | Director | Sale of securities on an exchange or to another person at price $ 34.09 per share. | 20 Sep 2021 | 500 | 9,013 (0%) | 0% | 34.1 | 17,045 | Common Stock |
| Jeffrey S. Flier | Director | Sale of securities on an exchange or to another person at price $ 31.48 per share. | 26 Jul 2021 | 3,037 | 28,272 (0%) | 0% | 31.5 | 95,606 | Common Stock |
| Jeffrey S. Flier | Director | Sale of securities on an exchange or to another person at price $ 31.84 per share. | 26 Jul 2021 | 2,963 | 31,309 (0%) | 0% | 31.8 | 94,348 | Common Stock |
| Michael Gilman | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 May 2021 | 7,800 | 7,800 | - | - | Stock Option (Right to Buy) | |
| David Hallal | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 May 2021 | 7,800 | 7,800 | - | - | Stock Option (Right to Buy) | |
| Akshay K. Vaishnaw | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 May 2021 | 7,800 | 7,800 | - | - | Stock Option (Right to Buy) | |
| Kristina Burow | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 May 2021 | 7,800 | 7,800 | - | - | Stock Option (Right to Buy) | |
| Amir H. Nashat | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 May 2021 | 7,800 | 7,800 | - | - | Stock Option (Right to Buy) | |
| Jeffrey S. Flier | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 May 2021 | 7,800 | 7,800 | - | - | Stock Option (Right to Buy) | |
| Joshua Reed | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Mar 2021 | 15,600 | 15,600 | - | - | Stock Options (Right to Buy) | |
| Michael Gilman | Director | Sale of securities on an exchange or to another person at price $ 65.59 per share. | 15 Mar 2021 | 4,696 | 37,459 (0%) | 0% | 65.6 | 307,998 | Common Stock |
| Michael Gilman | Director | Sale of securities on an exchange or to another person at price $ 65.06 per share. | 08 Feb 2021 | 1,804 | 42,155 (0%) | 0% | 65.1 | 117,361 | Common Stock |
| Edward H. Myles | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2021 | 80,500 | 346,301 | - | - | Stock Option (Right to Buy) | |
| Edward H. Myles | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2021 | 24,150 | 24,150 (0%) | 0% | 0 | Common Stock | |
| Yung H. Chyung | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2021 | 52,500 | 225,534 | - | - | Stock Option (Right to Buy) | |
| Yung H. Chyung | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2021 | 15,750 | 15,750 (0%) | 0% | 0 | Common Stock | |
| Gregory John Carven | Head of Research | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2021 | 12,600 | 12,600 (0%) | 0% | 0 | Common Stock | |
| Gregory John Carven | Head of Research | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2021 | 42,000 | 177,631 | - | - | Stock Option (Right to Buy) | |
| Michael Gilman | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.77 per share. | 26 Jan 2021 | 2,188 | 46,147 (0%) | 0% | 5.8 | 12,625 | Common Stock |
| Michael Gilman | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Jan 2021 | 2,188 | 1,314 | - | - | Stock Option (Right to Buy) | |
| Michael Gilman | Director | Sale of securities on an exchange or to another person at price $ 59.90 per share. | 26 Jan 2021 | 1,518 | 43,959 (0%) | 0% | 59.9 | 90,928 | Common Stock |
| Michael Gilman | Director | Sale of securities on an exchange or to another person at price $ 59.02 per share. | 26 Jan 2021 | 1,500 | 45,477 (0%) | 0% | 59.0 | 88,533 | Common Stock |
| Michael Gilman | Director | Sale of securities on an exchange or to another person at price $ 57.99 per share. | 26 Jan 2021 | 483 | 46,977 (0%) | 0% | 58.0 | 28,008 | Common Stock |
| Michael Gilman | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.77 per share. | 26 Jan 2021 | 1,313 | 47,460 (0%) | 0% | 5.8 | 7,576 | Common Stock |
| Michael Gilman | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Jan 2021 | 1,313 | 0 | - | - | Stock Option (Right to Buy) | |
| Gregory John Carven | Head of Research | Sale of securities on an exchange or to another person at price $ 55.87 per share. | 26 Jan 2021 | 5,400 | 46,434 (0%) | 0% | 55.9 | 301,680 | Common Stock |
| Gregory John Carven | Head of Research | Sale of securities on an exchange or to another person at price $ 56.72 per share. | 26 Jan 2021 | 12,139 | 34,295 (0%) | 0% | 56.7 | 688,511 | Common Stock |
| Gregory John Carven | Head of Research | Sale of securities on an exchange or to another person at price $ 57.79 per share. | 26 Jan 2021 | 1,561 | 32,734 (0%) | 0% | 57.8 | 90,212 | Common Stock |
| Gregory John Carven | Head of Research | Sale of securities on an exchange or to another person at price $ 60.65 per share. | 26 Jan 2021 | 2,543 | 52,898 (0%) | 0% | 60.7 | 154,234 | Common Stock |
| Gregory John Carven | Head of Research | Sale of securities on an exchange or to another person at price $ 61.52 per share. | 26 Jan 2021 | 1,064 | 51,834 (0%) | 0% | 61.5 | 65,453 | Common Stock |
| Edward H. Myles | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jul 2020 | 250,000 | 250,000 | - | - | Stock Option (Right to Buy) | |
| Edward H. Myles | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2020 | 13,000 | 13,000 | - | - | Stock Option (right to buy) | |
| Michael Gilman | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2020 | 13,000 | 13,000 | - | - | Stock Option (right to buy) | |
| David Hallal | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2020 | 13,000 | 13,000 | - | - | Stock Option (right to buy) | |
| David Hallal | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2020 | 7,000 | 7,000 | - | - | Stock Option (right to buy) | |
| Akshay K. Vaishnaw | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2020 | 13,000 | 13,000 | - | - | Stock Option (right to buy) | |
| Kristina Burow | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2020 | 13,000 | 13,000 | - | - | Stock Option (right to buy) | |
| Amir H. Nashat | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2020 | 13,000 | 13,000 | - | - | Stock Option (right to buy) | |
| Jeffrey S. Flier | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2020 | 13,000 | 13,000 | - | - | Stock Option (right to buy) | |
| Alan J. Buckler | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2020 | 75,000 | 75,000 | - | - | Stock Option (Right to Buy) | |
| Yung H. Chyung | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2020 | 75,000 | 75,000 | - | - | Stock Option (Right to Buy) | |
| Nagesh K. Mahanthappa | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2020 | 164,000 | 164,000 | - | - | Stock Option (Right to Buy) | |
| Erin Moore | SVP, Finance | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2020 | 50,600 | 50,600 | - | - | Stock Option (Right to Buy) | |
| Erin Moore | SVP, Finance | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Dec 2019 | 9,400 | 9,400 | - | - | Stock Option (Right to Buy) | |
| Timothy A. Springer | Ten Percent Owner | Gift of securities by or to the insider at price $ 0.00 per share. | 10 Dec 2019 | 296,000 | 2,376,567 (8%) | 0% | 0 | Common Stock | |
| David Hallal | None | Gift of securities by or to the insider at price $ 0.00 per share. | 18 Sep 2019 | 2,000 | 290,595 (0%) | 0% | 0 | Common Stock | |
| Timothy A. Springer | Ten Percent Owner | Gift of securities by or to the insider at price $ 0.00 per share. | 19 Aug 2019 | 296,000 | 2,672,567 (9%) | 0% | 0 | Common Stock | |
| Edward H. Myles | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 May 2019 | 5,079 | 5,079 | - | - | Stock Option (Right to Buy) | |
| Michael Gilman | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 May 2019 | 10,158 | 10,158 | - | - | Stock Option (Right to Buy) | |
| David Hallal | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 May 2019 | 10,158 | 10,158 | - | - | Stock Option (Right to Buy) | |
| Akshay K. Vaishnaw | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 May 2019 | 20,316 | 20,316 | - | - | Stock Option (Right to Buy) | |
| Kristina Burow | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 May 2019 | 10,158 | 10,158 | - | - | Stock Option (Right to Buy) | |
| Amir H. Nashat | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 May 2019 | 10,158 | 10,158 | - | - | Stock Option (Right to Buy) | |
| Jeffrey S. Flier | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 May 2019 | 10,158 | 10,158 | - | - | Stock Option (Right to Buy) | |
| Alan J. Buckler | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2019 | 51,000 | 51,000 | - | - | Stock Option (Right to Buy) | |
| Rhonda M. Chicko | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2019 | 56,000 | 56,000 | - | - | Stock Option (Right to Buy) | |
| Yung H. Chyung | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2019 | 56,000 | 56,000 | - | - | Stock Option (Right to Buy) | |
| Nagesh K. Mahanthappa | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2019 | 130,000 | 130,000 | - | - | Stock Option (Right to Buy) | |
| Edward H. Myles | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Nov 2018 | 20,316 | 20,316 | - | - | Stock Option (right to buy) | |
| Michael Gilman | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2018 | 20,316 | 20,316 | - | - | Stock Option (right to buy) | |
| David Hallal | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2018 | 20,316 | 20,316 | - | - | Stock Option (right to buy) | |
| Kristina Burow | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2018 | 20,316 | 20,316 | - | - | Stock Option (right to buy) | |
| Amir H. Nashat | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2018 | 20,316 | 20,316 | - | - | Stock Option (right to buy) | |
| Timothy A. Springer | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2018 | 20,316 | 20,316 | - | - | Stock Option (right to buy) | |
| Jeffrey S. Flier | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2018 | 20,316 | 20,316 | - | - | Stock Option (right to buy) | |
| Elan Ezickson | COO & Head of Corp.Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 May 2018 | 8,757 | 8,757 | - | - | Stock Option (Right to Buy) | |
| Kristina Burow | None | 29 May 2018 | 1,575,299 | 0 | - | - | Series A-4 Preferred | ||
| Kristina Burow | None | 29 May 2018 | 1,249,999 | 0 | - | - | Series A-2 Preferred | ||
| Kristina Burow | None | 29 May 2018 | 1,811,595 | 0 | - | - | Series A-3 Preferred | ||
| Kristina Burow | None | 29 May 2018 | 293,813 | 2,637,617 (10%) | 1% | 0 | Common Stock | ||
| Kristina Burow | None | 29 May 2018 | 719,559 | 2,343,804 (9%) | 2% | 0 | Common Stock | ||
| Kristina Burow | None | 29 May 2018 | 551,807 | 1,624,245 (6%) | 2% | 0 | Common Stock | ||
| Kristina Burow | None | 29 May 2018 | 634,579 | 1,072,438 (4%) | 2% | 0 | Common Stock | ||
| Kristina Burow | None | 29 May 2018 | 437,859 | 437,859 (1%) | 1% | 0 | Common Stock | ||
| Kristina Burow | None | 29 May 2018 | 838,780 | 0 | - | - | Series C Preferred | ||
| Kristina Burow | None | 29 May 2018 | 2,054,197 | 0 | - | - | Series B Preferred | ||
| Amir H. Nashat | Director, Ten Percent Owner | 29 May 2018 | 693,294 | 2,258,251 (9%) | 2% | 0 | Common Stock | ||
| Amir H. Nashat | Director, Ten Percent Owner | 29 May 2018 | 944,789 | 0 | - | - | Series A-1 Preferred Stock | ||
| Amir H. Nashat | Director, Ten Percent Owner | 29 May 2018 | 55,211 | 0 | - | - | Series A-1 Preferred Stock | ||
| Amir H. Nashat | Director, Ten Percent Owner | 29 May 2018 | 1,409,429 | 0 | - | - | Series A-2 Preferred Stock | ||
| Amir H. Nashat | Director, Ten Percent Owner | 29 May 2018 | 82,363 | 0 | - | - | Series A-2 Preferred Stock | ||
| Amir H. Nashat | Director, Ten Percent Owner | 29 May 2018 | 1,369,259 | 0 | - | - | Series A-3 Preferred Stock | ||
| Amir H. Nashat | Director, Ten Percent Owner | 29 May 2018 | 80,016 | 0 | - | - | Series A-3 Preferred Stock | ||
| Amir H. Nashat | Director, Ten Percent Owner | 29 May 2018 | 744,162 | 0 | - | - | Series A-4 Preferred Stock | ||
| Amir H. Nashat | Director, Ten Percent Owner | 29 May 2018 | 43,487 | 0 | - | - | Series A-4 Preferred Stock | ||
| Amir H. Nashat | Director, Ten Percent Owner | 29 May 2018 | 1,979,216 | 0 | - | - | Series B Preferred Stock | ||
| Amir H. Nashat | Director, Ten Percent Owner | 29 May 2018 | 115,659 | 0 | - | - | Series B Preferred Stock | ||
| Amir H. Nashat | Director, Ten Percent Owner | 29 May 2018 | 808,166 | 0 | - | - | Series C Preferred Stock | ||
| Amir H. Nashat | Director, Ten Percent Owner | 29 May 2018 | 47,225 | 0 | - | - | Series C Preferred Stock | ||
| Amir H. Nashat | Director, Ten Percent Owner | 29 May 2018 | 330,948 | 330,948 (1%) | 1% | 0 | Common Stock | ||
| Amir H. Nashat | Director, Ten Percent Owner | 29 May 2018 | 19,340 | 19,340 (0%) | 0% | 0 | Common Stock | ||
| Amir H. Nashat | Director, Ten Percent Owner | 29 May 2018 | 493,705 | 824,653 (3%) | 2% | 0 | Common Stock | ||
| Amir H. Nashat | Director, Ten Percent Owner | 29 May 2018 | 28,851 | 48,191 (0%) | 0% | 0 | Common Stock | ||
| Amir H. Nashat | Director, Ten Percent Owner | 29 May 2018 | 479,634 | 1,304,287 (5%) | 1% | 0 | Common Stock | ||
| Amir H. Nashat | Director, Ten Percent Owner | 29 May 2018 | 28,028 | 76,219 (0%) | 0% | 0 | Common Stock | ||
| Amir H. Nashat | Director, Ten Percent Owner | 29 May 2018 | 260,670 | 1,564,957 (6%) | 1% | 0 | Common Stock | ||
| Amir H. Nashat | Director, Ten Percent Owner | 29 May 2018 | 15,233 | 91,452 (0%) | 0% | 0 | Common Stock | ||
| Amir H. Nashat | Director, Ten Percent Owner | 29 May 2018 | 40,514 | 131,966 (0%) | 0% | 0 | Common Stock | ||
| Amir H. Nashat | Director, Ten Percent Owner | 29 May 2018 | 283,090 | 2,541,341 (10%) | 1% | 0 | Common Stock | ||
| Amir H. Nashat | Director, Ten Percent Owner | 29 May 2018 | 16,542 | 148,508 (0%) | 0% | 0 | Common Stock | ||
| Amir H. Nashat | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 14.00 per share. | 29 May 2018 | 134,970 | 2,676,311 (10%) | 0% | 14 | 1,889,580 | Common Stock |
| Amir H. Nashat | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 14.00 per share. | 29 May 2018 | 7,887 | 156,395 (0%) | 0% | 14 | 110,418 | Common Stock |
| Timothy A. Springer | Director, Ten Percent Owner | 29 May 2018 | 855,391 | 0 | - | - | Series C Preferred | ||
| Timothy A. Springer | Director, Ten Percent Owner | 29 May 2018 | 733,808 | 2,902,459 (11%) | 3% | 0 | Common Stock | ||
| Timothy A. Springer | Director, Ten Percent Owner | 29 May 2018 | 787,649 | 0 | - | - | Series A-4 Preferred | ||
| Timothy A. Springer | Director, Ten Percent Owner | 29 May 2018 | 299,632 | 3,202,091 (13%) | 1% | 0 | Common Stock | ||
| Timothy A. Springer | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 14.00 per share. | 29 May 2018 | 71,428 | 3,273,519 (13%) | 0% | 14 | 999,992 | Common Stock |
| Timothy A. Springer | Director, Ten Percent Owner | 29 May 2018 | 275,903 | 275,903 (1%) | 1% | 0 | Common Stock | ||
| Timothy A. Springer | Director, Ten Percent Owner | 29 May 2018 | 350,287 | 1,138,433 (4%) | 1% | 0 | Common Stock | ||
| Timothy A. Springer | Director, Ten Percent Owner | 29 May 2018 | 522,556 | 1,660,989 (6%) | 2% | 0 | Common Stock | ||
| Timothy A. Springer | Director, Ten Percent Owner | 29 May 2018 | 507,662 | 2,168,651 (8%) | 2% | 0 | Common Stock | ||
| Timothy A. Springer | Director, Ten Percent Owner | 29 May 2018 | 1,000,000 | 0 | - | - | Series A-1 Preferred | ||
| Timothy A. Springer | Director, Ten Percent Owner | 29 May 2018 | 1,491,792 | 0 | - | - | Series A-2 Preferred | ||
| Timothy A. Springer | Director, Ten Percent Owner | 29 May 2018 | 1,449,275 | 0 | - | - | Series A-3 Preferred | ||
| Timothy A. Springer | Director, Ten Percent Owner | 29 May 2018 | 2,094,875 | 0 | - | - | Series B Preferred | ||
| Alan J. Buckler | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 May 2018 | 15,838 | 15,838 | - | - | Stock Option (Right to Buy) | |
| Rhonda M. Chicko | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 May 2018 | 15,208 | 15,208 | - | - | Stock Option (Right to Buy) | |
| Nagesh K. Mahanthappa | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 May 2018 | 147,295 | 147,295 | - | - | Stock Option (Right to Buy) |